Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Robinson

Neurological Surgery Birmingham, AL Medical Doctor

NPI 1851331698 CMS profile 529877

513 Brookwood Blvd, Ste 75, Birmingham, AL 35209

Open in the dashboard

General payments

$6,907

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Robinson of Birmingham, AL is reported in the CMS Open Payments database as having received $6,907 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,528 39
2024 General $1,226 33
2023 General $1,478 44
2022 General $1,379 58
2021 General $653 26
2020 General $221 13
2019 General $422 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Robinson
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Robert Robinson were reported at $1,528. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Robert Robinson Neurological Surgery median Middle half National median
2019 $422 $582 $138–$3,006 $163
2020 $221 $294 $76–$2,174 $114
2021 $653 $387 $105–$2,432 $132
2022 $1,379 $542 $139–$2,989 $149
2023 $1,478 $534 $145–$2,697 $160
2024 $1,226 $574 $155–$3,046 $164
2025 $1,528 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,444 83 payments
  2. Carlsmed, Inc. $1,125 17 payments
  3. Providence Medical Technology, Inc. $917 15 payments
  4. Medtronic, Inc. $486 12 payments
  5. NuVasive, Inc. $411 18 payments
  6. DePuy Synthes Sales Inc. $367 14 payments
  7. Ethicon US, LLC $277 9 payments
  8. ulrich medical USA, Inc. $237 1 payment
  9. Radius Health, Inc. $225 9 payments
  10. Globus Medical, Inc. $204 5 payments
  11. Other $1,214 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,879 232 payments
  2. Education $27 2 payments
Products named General payments · program years 2019–2025
  1. aprevo $1,125 17 payments
  2. WaveWriter Alpha Prime 16 $1,055 53 payments
  3. Tymlos $225 9 payments
  4. SYMPHONY $181 6 payments
  5. Spectra WaveWriter $166 5 payments
  6. ECM Patch,Pouch $160 3 payments
  7. CD HORIZON SPINAL SYSTEM $145 3 payments
  8. INTEGRATE-C $138 1 payment
  9. XLIF $132 6 payments
  10. Prospera $117 4 payments
  11. Other $2,606 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

479

Median for Neurosurgery: 83

Drug cost

$4,333

Median for Neurosurgery: $872

Branded share of claims

42%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 98 $1,084
Gabapentin Generic 135 $1,058
Methocarbamol Generic 100 $1,024
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 103 $784
Diclofenac Sodium Generic 12 $189
Methylprednisolone Generic 18 $168
Meloxicam Generic 13 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$209,322

Medicare's payments for the services billed

Medicare patients

287

Average age 71

Services billed

854

157 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Ischemic heart disease 35%
Depression 34%
Chronic kidney disease 23%
COPD 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record